Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mirjam J.G. van Manen, Surinder S. Birring, Carlo Vancheri, Virginia Vindigni, Elisabetta Renzoni, Anne-Marie Russell, Monique Wapenaar, Vincent Cottin, Marlies S. Wijsenbeek. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017

Member's Comments

No comment yet.

Related content which might interest you: Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020 Year: 2020 Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Cough in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2016; 25: 278-286 Year: 2016 Exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2016 – Russia Session Year: 2016 Idiopathic pulmonary fibrosis and pirfenidone Source: Eur Respir J 2010; 35: 728-729 Year: 2010 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis Source: Eur Respir J, 49 (5) 1601339; 10.1183/13993003.01339-2016 Year: 2017 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Patients with idiopathic pulmonary fibrosis and chronic obstructive lung disease leak inhaled nanoparticles to the blood. Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling Year: 2019 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017